Diabetes drug and biotechnology firm Amylin Pharmaceuticals Inc. claimed that their second-quarter losses have now narrowed. This is largely due to sales of the diabetes drug Byetta.
The figures are improving for the company, but a substantial loss is still being made. The company lost $45 million, approximately 34 cents per share . Revenue climbed to $197 million, largely aided by diabetic medication Byetta. Another drug for diabetics, Symli, generated revenue of $15.2 million.
Revenue from collaborative agreements was also found to surge. Eli Lilly and Co are co-releasing Byetta in the European Unio, and milestone payments between the two companies are aiding Amylin fortunes.
Byetta faces stiff resistance from a Merck rival drug, Januvia.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…